Hong Kong
· Delayed Price · Currency is HKD Abbisko Cayman Company Description
Abbisko Cayman Limited, an investment holding company, engages in the research and development of pharmaceutical products in the People’s Republic of China.
The company develops Pimicotinib, which is in Phase III clinical trial for the treatment of tenosynovial giant cell tumor; Irpagratinib for the treatment of hepatocellular carcinoma; ABSK043 that is in Phase I clinical trial for the treatment of non-small cells lung cancer; and ABSK061 for the treatment of solid tumors.
It also develops Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3; ABSK112, an EGFR Exon20ins inhibitor with selectivity over wild-type EGFR and brain-penetration activity; Mavorixafor, an orally bioavailable CXCR4 modulator; and ABSK051, a small molecule CD73 inhibitor for the treatment of various tumor types, such as lung and pancreatic cancer.
In addition, the company develops ABSK012, which is in Phase I clinical trial for treatment of soft tissue sarcoma; ABK131, a selective MTA-cooperative and brain-penetrant PRMT5 inhibitor; ABK3376, which is in Phase I clinical trial for the treatment of NSCLC harboring the EGFR-C797S mutation; and ABSK141, an orally bioavailable small-molecule KRAS-G12D inhibitor.
Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 281 |
| CEO | Yao-Chang Xu |
Contact Details
Address: Building 3, No. 898 Shanghai China | |
| Phone | 86 21 6891 2098 |
| Website | abbisko.com |
Stock Details
| Ticker Symbol | 2256 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG0028A1085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yao-Chang Xu | Founder, Chairman of the Board and Chief Executive Officer |
| Dr. Hongping Yu | Co-Founder, Jt Co Secretary, Senior Vice President of Chemistry, Chief Scientific Officer and Executive Director |
| Dr. Zidong Zhang | Chief Financial Officer |
| Jia Feng | Vice President of Human Resources and Operations and Head of Human Resource |
| Yongyi Li | General Counsel |
| Dr. Zhen Zhang | Vice President of CMC and Head of Chemistry, Manufacturing and Controls |
| Dr. Jing Ji | Chief Medical Officer and Executive Director |
| Yin Wah Chan FCCA, FCIS, FCS, HKICS | Joint Company Secretary |